Investigation of Burkholderia cepacia nosocomial outbreak with high
fatality in patients suffering from diseases other than cystic fibrosis.
Shehabi AA, Abu-Al-Soud W, Mahafzah A, Khuri-Bulos N, Abu Khader I,
Ouis IS, Wadstrom T.
Department of Clinical Laboratories, Jordan University Hospital, Amman,
Over a 1-y period, 26 inpatients
at the Jordan University Hospital in Amman were detected with bacteraemia (23
cases) or respiratory tract colonized with B. cepacia (3 cases). A combination
of genetic identification and molecular typing has proved that all cases were
caused by a single epidemic strain of B. cepacia genomovar IIIa. Nosocomial
infections could be documented in 21/26 (81%) patients, mostly with severe
underlying or malignant diseases other than cystic fibrosis, but the source of
infection was undetected. The overall mortality related to infection with B.
cepacia was 42%. All B. cepacia isolates were resistant to ampicillin, amikacin,
carbenicillin and gentamicin; and mostly susceptible to piperacillin,
chloramphenicol, cotri-moxazole, tetracycline, ceftazidime, and tazocin
(62-88%). This study demonstrates the nosocomial and high fatality of B. cepacia
genomovar IIIa in Jordanian patients suffering from diseases other than cystic